Search

Displaying results 4081 - 4090 of 8974 in total
  1. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  2. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    Etamivan (INN) or ethamivan (USAN) is marketed under the name Analepticon. Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.

  3. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen … Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides.

  4. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. … GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets.

  5. Drug

    Teplinovivint

    go.drugbank.com/drugs/DB21475
    Experimental

    The usage of the INN stem '-vivint' in the name indicates that Teplinovivint is a Wnt signaling inhibitor. Teplinovivint has a monoisotopic molecular weight of 442.21 Da.

  6. Drug

    Ipivivint

    go.drugbank.com/drugs/DB21479
    Experimental

    The usage of the INN stem '-vivint' in the name indicates that Ipivivint is a Wnt signaling inhibitor. Ipivivint has a monoisotopic molecular weight of 464.19 Da.

  7. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

  8. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  9. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals. … PW2101 is a beta blocker intended for the treatment of hypertension and angina.